Abstract 2299
Background
Chemoradiation is the current standard of care for advanced cervical cancer, however radiation is associated with long term side effects that may impair the quality of life of survivors. Recent findings from observational and case series suggest that women with stage IB2, IIA, and IIB who respond to neoadjuvant chemotherapy might be a candidate for radical surgery as the definitive treatment. This approach can reduce long-term complications associated with chemoradiation and improve patient quality of life.
Trial design
Eligible patients are women aged ≥ 18y diagnosed with invasive cervical cancer stages IB2, IIA or IIB. The stage will be assessed by clinical examination and confirmed by pelvic MRI, CT of upper abdomen and CT of thorax. ECOG PS 0-1 and adequate organ function are required. Two hundred and forty-four patients will be randomly assigned to one of two arms. In arm 1, patients will receive standard chemoradiation (cisplatin 40mg/m2 IV: D1, D8, D15, D29 and D36 in concomitancy with external radiation 50.4Gy fractionated in 28 sessions of 1,8Gy followed by brachytherapy in four insertions of 7 Gy). In arm 2, patients will receive intravenous neoadjuvant chemotherapy (cisplatin 75mg/m2 D1 plus paclitaxel 80mg/m2) D1, D8 e D15, each 21 days, 3 cycles. After each cycle, the patient will be evaluated to verify toxicity and tumor response. After the third cycle, the patients with a complete clinical response or substantial tumor reduction (tumor restricted to cervix ≤4 cm), confirmed by pelvic MRI will undergo Piver-Rutledge class III abdominal hysterectomy and pelvic lymphadenectomy 3-6 weeks after the last cycle. Patients with tumor progression or severe toxicity after any cycle of neoadjuvant chemotherapy, or with inoperable tumor after the third cycle of neoadjuvant chemotherapy will be treated with definitive standard chemoradiation. The primary end point will be 5-years overall survival. Secondary endpoints will include survival free of disease, the rate of operability and complete pathological response in the neoadjuvant arm. The study is ongoing; one patient has been included, and three more are under preliminary evaluation for eligibility.
Clinical trial identification
UTN: U1111-1213-5169.
Legal entity responsible for the study
Division of Gynecologic Oncology - Department of Gynecology and Obstetrics - Ribeirão Preto Medical School - University of São Paulo.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract